However, when survival analyses were performed to evaluate the cancer-specific survival in the presence of FGFR4 polymorphism genotypes, the authors found that cases with the Arg388 allele experienced significantly worse cancer-specific survival relative to those with only the Gly388 allele (P = 0.04). This evidence concerns the gene FGFR4 and cancer.